Project description
Assessing R21/M-Malaria vaccine's extended protection in African children
Post-discharge malaria chemoprevention is a strategy to reduce death and re-hospitalisation in children recovering from severe anaemia. However, it only protects for up to four months after discharge, even though the risk of mortality and morbidity lasts for up to one year. The EU-funded R21-PD project aims to provide scientific evidence for the World Health Organization (WHO) on the long-term efficacy, safety, acceptability and cost-effectiveness of the R21/Matrix-Malaria vaccine. It aims to extend malaria prevention from four months to 12 months for children in malaria-endemic regions of sub-Saharan Africa. The project will conduct a randomised controlled clinical trial in Kenya, Malawi and Uganda, along with sub-studies, to assess immunogenicity, acceptability and cost-effectiveness.
Objective
The overall goal of this project is to provide scientific evidence for WHO policymaking on the longterm efficacy, safety, acceptability and cost-effectiveness of using R21/Matrix-Malaria vaccine to extend the duration of malaria chemoprevention from 4 to 12 months in children recovering from severe anaemia in highly malaria-endemic areas in sub-Saharan Africa. This project will generate long-term safety and efficacy data and also generate pharmacovigilance data on a currently registered vaccines of R21/M-malaria vaccine in a under-studied patient population group.
Post-discharge Malaria Chemoprevention, a malaria control strategy recently recommended by WHO to reduce the risk of death or re-hospitalization in children recovering from severe anaemia. However this strategy only provides this protection during the first 3-4 months post-discharge, although their risk of mortality and morbidity extends over 12 months. This project will determine whether providing R21 malaria vaccine will provide this extended malaria protection.
We shall conduct a randomised-controlled clinical trial in Malawi, Kenya and Uganda to determine whether providing a booster dose of R21 malaria vaccine will reduce death and re-hospitalizations over a 12-month follow-up period compared to providing PDMC over 3 months with a monthly treatment course of an antimalarial (DP) in children recovering from severe anaemia. We shall also conduct sub-studies in order to determine the immunogenicity, acceptability from the patient and providers’ perspective and the cost-effectiveness including a budget impact analysis of this intervention. Lastly, we shall engage local and international policymakers to facilitate uptake of our findings and possible policy adoption.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- medical and health sciences health sciences infectious diseases parasitic diseases malaria
- social sciences sociology demography mortality
- medical and health sciences basic medicine pharmacology and pharmacy pharmaceutical drugs vaccines
You need to log in or register to use this function
Keywords
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
HORIZON.2.1 - Health
MAIN PROGRAMME
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
HORIZON-JU-RIA - HORIZON JU Research and Innovation Actions
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) HORIZON-JU-GH-EDCTP3-2024-01-two-stage
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
L3 5QA LIVERPOOL 3
United Kingdom
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.